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Introduction: The prescription of physical activity for hospitalized patients with acute 
exacerbation of chronic obstructive pulmonary disease (AECOPD) can be complicated by the 
presence of comorbidities. The current research aimed to synthesize the relevant literature on 
the benefits of exercise for people with multimorbidities who experience an AECOPD, and 
ask: What are the parameters and outcomes of exercise in AECOPD and in conditions that are 
common comorbidities as reported by systematic reviews (SRs)?
Methods: An SR was performed using the Cochrane Collaboration protocol. Nine electronic 
databases were searched up to July 2011. Articles were included if they (1) described partici-
pants with AECOPD, chronic obstructive pulmonary disease (COPD), or one of eleven common 
comorbidities, (2) were an SR, (3) examined aerobic training (AT), resistance training (RT), 
balance training (BT), or a combination thereof, (4) included at least one outcome of fitness, 
and (5) compared exercise training versus control/sham.
Results: This synthesis examined 58 SRs of exercise training in people with AECOPD, COPD, 
or eleven chronic conditions commonly associated with COPD. Meta-analyses of endurance 
(aerobic or exercise capacity, 6-minute walk distance – 6MWD) were shown to significantly 
improve in most conditions (except osteoarthritis, osteoporosis, and depression), whereas 
strength was shown to improve in five of the 13 conditions searched: COPD, older adults, heart 
failure, ischemic heart disease, and diabetes. Several studies of different conditions also reported 
improvements in quality of life, function, and control or prevention outcomes. Meta-analyses 
also demonstrate that exercise training decreases the risk of mortality in older adults, and those 
with COPD or ischemic heart disease. The most common types of training were AT and RT. 
BT and functional training were commonly applied in older adults. The quality of the SRs for 
most conditions was moderate to excellent (.65%) as evaluated by AMSTAR scores.
Conclusion: In summary, this synthesis showed evidence of significant benefits from exercise 
training in AECOPD, COPD, and conditions that are common comorbidities. A broader approach 
to exercise and activity prescription in pulmonary rehabilitation may induce therapeutic benefits 
to ameliorate clinical sequelae associated with AECOPD and comorbidities such as the inclusion 
of BT and functional training.
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Introduction
Chronic obstructive pulmonary disease (COPD) is the fifth leading cause of death 
in the world and the mortality rate is expected to increase more than 30% during 
the next 10 years.1 Acute exacerbations of COPD (AECOPD) are common and are 
a key predictor of increased morbidity, health care costs, and mortality. The Global 
Initiative for Lung Disease (GOLD)1 defines a COPD exacerbation as “an event in 
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the natural course of the disease characterized by a change 
in the patient’s baseline dyspnea, cough and/or sputum that 
is beyond normal day-to-day variation, is acute in onset, and 
may warrant a change in regular medication in a patient with 
underlying COPD”. Most patients with COPD have at least 
one exacerbation per year; a substantial proportion of patients 
(17%) have three or more episodes per year.2,3
Many exacerbations of COPD are managed on an 
outpatient basis, but if the patient is hospitalized, the length 
of stay (LOS) is prolonged: the median LOS in Canadian 
hospitals is 13 days,4 which translates to an estimated cost of 
CAD$9500 per hospitalization.5 Premature discharge result-
ing in shorter LOS, however, is associated with increased 
readmission and mortality.6
Hospitalization to treat acute illness can have a 
detrimental effect on muscle performance.7 Muscle impair-
ment and functional decline have been well-documented in 
older hospitalized patients, and have been attributed to the 
consequences of hospitalization rather than the admitting 
illness.8–11 In a previous study on 1181 hospitalized patients 
with acute medical illnesses (circulatory, 27%; respiratory, 
20%; gastrointestinal, 15%; cancer, 6%), 17% of patients 
required assistance with mobility on discharge, despite being 
able to walk independently prior to admission.12 Pitta et al 
reported that patients who are hospitalized with an acute 
exacerbation of COPD spend the majority of their time 
sitting, and do not return to their baseline level of activity 
even after 1 month post-discharge.13
Caring for hospitalized patients with AECOPD can be 
complicated by the presence of other chronic conditions, 
which can also influence the severity of the exacerbation and 
the health outcomes of the patient. Individuals with COPD 
have a higher risk of multimorbidity14–27 (Table 1) than indi-
viduals with other chronic illnesses. Despite this, there has 
been widespread failure to address the complexities inher-
ent in living with multiple chronic illnesses simultaneously, 
especially in the hospitalized, acutely ill population. Devising 
exercise plans for hospitalized AECOPD patients living with 
multimorbidity is complicated by the limitations imposed by 
the acute exacerbation and by the synergistic effect of the 
multiple conditions upon the person. While recent reviews 
have examined evidence regarding the effectiveness of exer-
cise therapy for people with multimorbidity in community 
settings,28,29 none have focused on hospitalized patients with 
COPD who also experience multi-morbidity. National physi-
cal activity guidelines fail to address this issue as well.30,31
Systematic reviews (SRs) provide a high level of evidence 
regarding the efficacy of therapeutic intervention, but the 
sheer number of available SRs on a given topic can make it 
difficult for the clinician to distill the important messages. 
Systematic reviews of systematic reviews have been pur-
ported as a way to both evaluate and summarize the key mes-
sages on important therapies, and are commonly published 
in areas of health care.32–36 The aim of the current research 
was to synthesize the relevant literature on the benefits of 
exercise for people with multimorbidity who are experienc-
ing an AECOPD. Thus we posed the question: What are the 
parameters and outcomes of exercise in AECOPD and in 
commonly associated comorbidities as reported by SRs?
Methods
Search strategy
A systematic review was performed using the methodology 
outlined by the Cochrane Collaboration protocol.37 Electronic 
databases were searched up to July 2011 including the 
Cochrane Controlled Trials Register, Cochrane-Systematic 
Reviews, MEDLINE, CINAHL (Cumulative Index to 
Nursing and Allied Health Literature), SPORTDiscus, 
EMBASE, PEDro (Physiotherapy Evidence Database), 
PsycINFO, and EBM reviews. Gray literature and reference 
lists from relevant articles were also reviewed to identify 
additional articles. Search terms were exemplified by the 
Table 1 Prevalence of chronic diseases in the population and in people with COPD
Chronic disease Prevalence in population Prevalence in COPD
Heart failure ,1% age 50–59; ∼7% age 80–8922 20%24
Ischemic heart disease 5% Severe and very severe COPD two-fold risk25
Peripheral arterial disease 4.3% at age 40, 14.5% at age 7020 Smokers OR 4.4620
Hypertension 15%; ∼50% $50 years18 1.6-fold risk25
Obesity 67% over age 3014 54%26
OA 13% at age 50; ∼40% at age 7523
Osteoporosis/osteopenia 15% over age 5021 60%–70%27
Diabetes mellitus – type 2 2.8% in 2000; 6.4% in 2010 with a 10.2% in the Western Pacific16 Increased relative risk 1.5–1.825
Depression 4.7% persistent depression or anxiety17 Depressive symptoms: 10%–80%25 
Depression that requires treatment: 19%–42%25
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MEDLINE search strategy (Appendix 1) and were modified 
accordingly to fit the requirements of the other databases.
Study criteria
Articles were included if they (1) described participants with 
AECOPD or COPD, or had one or more of the following con-
ditions that are common comorbidities: anxiety/depression, 
atherosclerosis, ischemic heart disease, peripheral vascular 
disease, heart failure, hypertension, diabetes mellitus, human 
immunodeficiency virus (HIV/AIDS), osteoarthritis (OA), 
osteoporosis, obesity/overweight, or older adults; (2) were 
SRs that included at least one randomized controlled trial 
(RCT); (3) examined an exercise intervention of aerobic 
training (AT), resistance training (RT), balance training (BT), 
or a combination thereof; (4) included at least one outcome of 
fitness; (5) had comparison groups of exercise training versus 
control/sham (that consisted of usual treatment, no exercise, 
or attention placebo); (6) were published in English. Articles 
were excluded if they (1) were published before 2000, or 
(2) investigated tai chi, yoga, or qi gong due to the multiple 
forms of these exercises and the difficulty in defining the 
expected training response to fitness outcomes. If two SRs 
reported on the same question and the majority of papers 
included were the same, only the SR with more articles and 
a more comprehensive review was included. Also, several 
SRs did not contain meta-analyses. These were reviewed if 
they met the criteria above, but data were extracted only if 
other reviews with meta-analyses were not available on the 
outcomes of interest.
Two individuals independently screened all titles and 
abstracts retrieved. Any discrepancies were discussed and 
resolved. From the selected abstracts, one person screened 
362 full text articles to determine if they met the inclusion 
criteria using a screening form. A second person was con-
sulted to confirm agreement on all articles to be excluded. 
The flow chart of the search strategy and study selection is 
summarized in Figure 1.
For each condition, one of the coauthors abstracted data 
and performed the quality assessment, which was double-
checked by at least one person. All discrepancies were 
discussed and reconciled. Data abstracted, when available, 
included (1) condition, age, and gender of participants, (2) the 
modality (Mo), frequency (Fr), intensity (I), time of session 
(T), and duration of program (D) of the exercise interven-
tion, (3) descriptors of the control, placebo, or sham group, 
and (4) outcomes of fitness, disease control or prevention, 
quality of life, and function.
Data related to functional training was abstracted. 
Functional training can be defined as mobility exercises that 
are functionally- or task-based rather than focused on strength 
Articles retrieved from 
grey literature 
n = 15
Titles and abstracts identified and 
screened n = 5080
Titles, abstracts retrieved and 
screened for eligibility 
n = 3276
Excluded duplicates 
n = 1804
Excluded   n = 2914 
- Not a systematic review 
- Participants did not have 
AECOPD or one of the co-
morbidities
- No exercise intervention 
- Not available in English 
- Published before 2000 
Systematic Reviews included in review    
n = 58
Citations retrieved 
from databases 
Medline
Embase    n = 2545 
n = 760 
n = 19 
n = 114 
n = 97 
n = 174 
n = 161 
n = 1210 
CINAHL 
Cochrane  CT 
Cochrane SR 
SportDiscus 
PEDro 
PsycINFO 
Full text articles screened for 
eligibility  n = 362 
Full text articles – abstracted data and 
quality assessment  ~120 
Excluded   n = 257 
- See reasons stated above 
Excluded   n = 62 
- See reasons stated above 
- Data duplicated in other 
systematic reviews 
Figure 1 Flow chart of retrieval, screening and inclusion of systematic reviews.
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training of particular muscle groups or endurance training 
to improve cardiovascular or aerobic status. Examples are 
stair climbing, repetitive sit to stand, and transfers. Such 
training often includes a combination of strength, endurance, 
and balance.
Quality assessment
All SRs were assessed using the AMSTAR quality assess-
ment tool.38 Scores for each item and totals are reported. Item 
11 was scored as “yes” if the conflict of interest was stated 
for the authors of the SR.
Data synthesis
Data was synthesized in tables that described the study qual-
ity (Table 2), the participants and interventions (Table 3), 
and outcomes (Table 4). An outcome was assigned to one of 
two categories based on whether it was measured in several 
conditions or if it was applied to evaluate a disease specific 
marker: (1) generic fitness (eg, exercise capacity, strength), 
quality of life, and functional outcomes (eg, timed up-and-go 
test, stair climbing), and (2) disease specific fitness, control, 
and prevention outcomes (eg, dyspnea, mortality, pain, ejec-
tion fraction, cholesterol levels).
Only statistically significant outcomes are reported in 
Table 4. When available, quantitative data for each meta-
analysis was described including the number of studies, 
the number of participants, the standardized effect size or 
weighted mean difference, risk ratio, odds ratio, and 95% 
confidence intervals. If this information was not available, 
an attempt was made to determine the number of studies 
that reported a significantly positive change versus the total 
number of studies that measured the outcome. Nonsignificant 
findings or trends are not reported.
Results
Study selection
A search of the eight databases yielded 3276 citations and 
abstracts after duplicates were removed. After independent 
screening of the citations by two reviewers, 362 full-text 
articles were selected and reviewed for inclusion. Fifteen 
additional articles were identified from manual searching 
of reference lists. The main reasons for excluding articles 
were that they were not an SR, that participants did not have 
COPD/AECOPD or one of the other conditions of the search 
strategy, there was no exercise intervention, the exercise 
intervention was not clearly described or not differentiated 
from concurrent treatment, there was no comparison between 
an exercise group and a control group, the SR reported on 
similar data but had few articles, the article was not available 
in English, or the article was published before 2000. No SRs 
were identified that compared exercise to a control group in 
people with asthma or bronchiectasis. Fifty-eight SRs met 
the inclusion criteria.
Quality assessment
The number of RCTs in any of the SRs that related to our ques-
tion ranged from 4 to 83. The average AMSTAR score was 
7.5 out of a potential 11. The most common items not reported 
were a list of excluded articles (only 26% of SRs provided 
this list), an examination of publication bias (ie, funnel plot 
or Egger regression test, which 45% reported), a statement 
regarding conflict of interest (50% reported), a selection 
and abstraction of data performed by two reviewers (65% 
reported), and a search of the gray literature (59% reported). 
All other items were addressed by $71% of the SRs.
Characteristics of participants
The age of participants ranged between 18 years and the “very 
elderly”. SRs that described people with HIV or depression 
had the youngest participants. Gender varied from 100% 
male to 100% female. SRs that described older adults had 
the largest sample sizes.
Characteristics of interventions  
and outcomes in the different  
chronic conditions
Characteristics of the interventions are detailed in Table 3, 
while outcomes in the different chronic conditions are shown 
in Table 4.
AECOPD
One SR investigated the benefits of aerobic and resistance 
training in people with COPD (AMSTAR of 11).39 Aerobic and 
resistance training of the extremities improved walk distance 
performance and quality of life measures in addition to decreas-
ing dyspnea, compared to the control group. Exercise also 
reduced admissions to hospital and mortality as demonstrated 
by meta-analyses of five and three RCTs, respectively.39 The 
SR included studies that initiated exercise immediately after 
or up to 6 weeks after treatment initiation for AECOPD as 
part of pulmonary rehabilitation on an out- or in-patient basis. 
Frequency of training ranged from three times a week to twice 
daily. The intensity of aerobic training was not reported.
COPD (stable)
Six SRs investigated the benefits of AT and RT in people with 
COPD, and the AMSTAR scores ranged between 5 and 10.40–45 
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Table 2 AMSTAR score
Condition Author AMSTAR scores
1 2 3 4 5 6 7 8 9 10 11 Total
AECOPD Puhan et al39 1 1 1 1 1 1 1 1 1 1 1 11
Chronic obstructive  
pulmonary disease
Lacasse et al42 1 1 1 1 1 1 1 1 1 0 1 10
O’Shea et al43 1 1 1 0 0 1 1 1 1 0 1 8
Salman et al44 1 0 1 1 0 1 1 1 1 1 0 8
Chavannes et al40 1 0 1 1 0 1 0 0 1 0 0 5
Vieira et al45 1 0 1 1 0 1 1 1 0 0 0 6
Janaudis-Ferreira et al41 1 0 1 1 0 1 1 0 0 0 0 5
Older adults Liu and Latham50 1 1 1 1 1 1 1 1 1 1 1 11
Howe et al49 1 1 1 1 1 1 1 1 1 0 1 10
Gillespie et al48 1 1 1 1 1 1 1 1 1 1 1 11
Weening-Dijksterhuis et al52 1 0 1 1 0 1 1 1 0 1 1 8
Forster et al47 1 1 1 1 0 0 0 0 0 0 1 5
Chin et al46 1 1 1 1 0 1 1 1 0 0 1 8
Rydwik et al51 1 0 1 1 0 1 1 1 0 0 0 6
Heart failure Davies et al55 1 0 1 0 0 0 1 1 1 1 1 7
Hwang et al54 1 1 1 0 0 1 1 1 1 1 0 8
Hwang and Marwick57 1 0 1 0 0 1 0 0 0 0 0 3
Chien et al53 1 1 1 1 0 1 1 0 1 0 0 7
Haykowsky et al56 1 1 1 1 0 1 1 1 0 1 0 8
van Tol et al58 1 1 1 0 0 0 1 1 1 1 0 7
Spruit et al61 1 1 1 0 0 1 1 1 0 0 0 6
Cahalin et al60 1 0 0 0 0 1 0 0 0 0 0 2
Benton59 1 0 0 0 0 1 0 0 0 0 0 2
Ischemic heart disease Haykowsky et al65 1 1 1 0 0 1 1 1 1 0 1 8
Valkeinen et al68 1 0 0 0 0 1 1 0 1 1 0 5
Cortes et al64 1 1 1 1 0 1 1 1 1 0 1 9
Jolliffe et al66 1 1 1 0 1 1 1 1 1 1 1 10
Clark et al62 1 1 1 0 0 1 1 1 1 1 1 9
Cornish et al63 1 0 1 0 0 1 0 0 0 0 0 3
Oliveira et al67 1 0 1 0 0 1 0 0 0 0 0 3
PVD Watson et al69 1 1 1 0 1 1 1 1 1 0 1 9
Wind and Koelemay70 1 1 1 0 0 0 1 1 1 1 0 7
Hypertension Dickinson et al73 1 1 1 0 1 0 1 1 1 1 0 8
Cornelissen and Fagard72 1 1 0 0 0 0 0 0 1 1 0 4
Whelton et al74 1 1 1 0 1 1 0 0 1 1 1 8
Kelley et al71 1 1 1 1 0 0 1 0 1 1 0 7
Obesity Shaw et al76 1 1 1 1 1 1 1 1 1 1 1 11
Witham and Avenell75 1 1 1 0 0 1 1 0 1 1 1 8
Osteoarthritis Devos-Comby et al79 1 0 1 1 0 1 1 1 1 1 0 8
Lange et al80 1 1 1 0 0 1 1 1 1 0 0 7
Ottawa Panel77 1 1 1 1 1 1 1 1 0 0 0 8
Brosseau et al78 1 1 1 1 0 1 1 1 0 0 0 7
Pelland et al81 1 1 1 1 1 1 1 1 1 0 0 9
Osteoporosis Li et al83 1 0 1 0 0 0 1 1 1 0 1 6
de Kam et al82 1 0 1 1 0 1 1 1 0 0 1 7
Diabetes mellitus Chudyk and Petrella85 1 0 1 1 0 1 0 0 1 0 1 6
Umpierre et al90 1 1 1 1 0 1 1 1 1 1 1 10
Irvine and Taylor86 1 1 1 0 0 1 1 1 1 0 0 7
Thomas et al89 1 1 1 1 1 1 1 1 1 1 1 11
Kelley and Kelley87 1 1 1 1 0 1 1 1 1 1 0 9
Snowling and Hopkins88 1 0 1 0 0 1 1 1 1 0 0 6
Boulé et al 84 1 0 1 1 0 1 1 0 1 0 0 6
HIV O’Brien et al91 1 1 1 1 1 1 1 1 1 0 1 10
Depression Krogh et al93 1 1 1 1 0 1 1 1 1 1 1 10
Herring et al94 1 0 1 1 0 0 1 1 1 1 1 8
Mead et al96 1 1 1 1 1 1 1 1 1 1 1 11
Rethorst et al95 1 1 1 1 0 1 1 0 1 0 1 8
Lawlor and Hopker92 1 1 1 1 0 1 1 1 1 0 1 9
Tallies for 58 reports 58 38 54 34 15 49 48 41 42 26 29 434
Percentage of total (58 reports) 100 66 93 59 26 84 83 71 72 45 50
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Table 3 Characteristics of participants and interventions
Author RCTs n (% M or F) Age (years) Characteristics of exercise intervention
AECOPD
Puhan et al39 9 427 (64% M) Range 62–70 Mo: AT and RT; Fr: Twice daily – 3×/week;  
T: NR except one study stated 2 hours/session;  
D: 10 days–6 months 
COPD
Lacasse et al42 31 1322 NR Mo: AT and RT, U/E, L/E, and/or respiratory  
muscle training; Fr and I: NR; D: 4–52 weeks
O’Shea et al43 9 of 18 296 of 679 (70% M) Range 48.5–72 Mo: RT using free weights, machine, Theraband;  
Fr: 2×/week–daily; I: variable; T: 5–12 reps,  
2–4 sets; D: 6–12 weeks
Salman et al44 20 999 59–73 Mo: AT, RT: U/E, L/E, and/or respiratory muscle  
training; Fr: $3 ×/week; D: 6 weeks–12 months;  
other details NR
Chavannes et al40 4 of 5 210 (∼55% M) 49–63 Mo: AT + RT (four studies), AT (one study);  
Fr: 2–7×/week; D: 8 weeks–18 months;  
other details NR
Vieira et al45 8 of 12 370 of 728 Range 38–78 Mo: Home-based AT and RT; Fr: 2×/week – twice 
daily; I: 90% of velocity of 6 MWD, $70%  
of maximal speed of SWT, cycle ergometer:  
30 W, cycling: 70% of work rate;  
T: 30–60 minutes; D: 4–52 weeks
Janaudis-Ferreira  
et al41
5 157 NR Mo: Arm AT and RT; Fr: 3×/week – 2×/day;  
I: NR; T: 4–10 reps 1–3 sets; D: 6–8 weeks
Older adults
Liu and Latham50 83 of 121 3059 of 6700 .60 Mo: RT in gym or against Theraband;  
Fr: 2–3×/week, except one was daily; I: ranged  
from low to high intensity; D: most 8–12 weeks  
but ranged from 2–104 weeks
Howe et al49 34 2883 (,50% M) 60–75 years Mo: RT, gait, balance, co-ordination, and functional 
tasks, tai chi, qi gong, dance, yoga; other details NR
Gillespie et al48 14 of 111 55303 (,50% M) .60 Mo: AT, RT, gait, balance and functional training,  
flexibility training, tai chi, and square stepping;  
general physical activity (walking groups);  
other details NR
Weening- 
Dijksterhuis et al52
27 6459 .70 Mo: RT (strength, resistance), ROM, balance,  
functional, gait, tai chi, flexibility; other details NR
Forster et al47 37 of 49 3611 
(33% M)
Mean 82 Mo: RT, AT (walking) and general daily living skills eg, 
eating, dressing, and climbing stairs, flexibility, balance; 
Fr: mean of 3.5×/week T: #30 minutes/week;  
D: 4 weeks–2 years
Chin et al46 20 2515 (majority F) 77–88 Mo: AT, RT, flexibility, balance, tai chi, and/or  
multi-component training; Fr: usually 3×/week;  
D: range 10–28 weeks
Rydwik et al51 16 1269 .70 Mo: RT, gait, and ROM training; Fr: usually 2–3×/week 
T: variable; D: 9 weeks–2 years
Heart failure
Davies et al55 19 3647 (majority M) 51–72 Mo: AT or AT + RT; Fr: 2–7×/week; I: 40% max  
HR or 85% VO2 max; T: 15–120 minutes;  
D: 24 weeks–3 years
Hwang et al54 4 of 8 103 (60% M) 62–77 Mo: RT for U/E and L/E; Fr: 2–3×/week;  
I: 60%–80% 1RM; T: 12–60 minutes; D: 8–22 weeks
Hwang and  
Marwick57
19 1069 (85% M) 59.05  
(95% CI 55–63)
Mo: AT or AT + RT: cycle ergometer, walking,  
calisthenics, ball games, strength training; Fr: NR;  
I: AT: −10% of AT, 60%–80% HRmax, 70% VO2 max 
RT: 80% 1RM, 70% HRmax;  
T: 40–400 minutes/week; D: 8–52 weeks
(Continued)
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Table 3 (Continued)
Author RCTs n (% M or F) Age (years) Characteristics of exercise intervention
Chien et al53 10 648 (79% M) 52–81 Mo: Home based AT (walking program, and/or cycle  
ergometer) and RT (added in 3/10 studies);  
Fr: 2–5×/week; I: 40%–70% HRmax, or 70% HR  
at VO2 max; T: 20–60 minutes; D: 6–52 weeks.  
All home programs
Haykowsky et al56 9 of 14 538 of 812 
(83% M)
52–61 Mo: AT: cycle ergometer, rowing, swimming, walking, 
arm ergometer, treadmill, interval training; Fr: 2–7 
days/week; I: 50%–80% VO2 peak, 60%–85% HRpeak, 
or 50%–70% max work load; T: 20–60 minutes; D: 
2–14 months
van Tol et al58 35 1486 (76% M) Mean 60.6  
(SD 7.5)
Mo: AT + RT; Fr: range 1–7×/week,  
mean 3.7×/week; I: 50%–80% VO2 peak, 60%–80%  
HRmax, 60%–80% HRR; T: 15–96 minutes,  
50 minutes (mean); D: 3–26 weeks, 13.0 weeks (mean)
Spruit et al61 4 of 10 114 (72% M) Mean 57–77 Mo: RT alone Fr: 2–3×/week; I: 40%–80% 1 RM;  
T: 15–60 reps in 1–3 sets; D: 8–20 weeks; progression 
described in some reports
Cahalin et al60 11 of 22 387 of 633 
(70% M)
30–80 Mo: RT: variety of strength exercises either alone or  
with short or long bursts of AT; Fr: 2–5×/week;  
I: RT: 20%–80% 1RM; AT: up to 80% VO2 peak,  
or 70% HRpeak, or 50% peak workload;  
T: 5–60 minutes; D: 4–26 weeks
Benton59 4 of 16 115 of 379 
(80% M)
Mean 30–76 Mo: RT: chair stands, heel lifts, weights, pulleys,  
hydraulic fitness; Fr: 2–3×/week, I: 60% 1 RM; AT: 
cycling, arm ergometer, stair climbing, walking;  
T: 2–60 minutes; D: 2–5 month study duration; reps 
and progression: variable
Ischemic heart disease
Haykowsky et al65 12 647 55 Mo: AT: Cycle, walk, jogging, calisthenics;  
Fr: 3–7×/week; I: 60%–80% VO2 max or peak HR;  
T: 30–180 minutes; D: 1–6 months
Valkeinen et al68 18 922 (majority M) 59.9 ± 4.9 Mo: AT: walking, jogging, cycling, and arm cranking;  
Fr: 3.1 ± 0.4×/week; I: 70%–80% HRmax, HRR,  
HR of anaerobic threshold or 25%–70% VO2 max;  
T: 20–60 minutes; D: 14.2 ± 13.5 weeks 
Mo: RT: Fr: 3.5 ± 0.7×/week; I: 50%–80% 1 RM or 
40%–60% MVC; T: 20–60 minutes; D: 22.0 ± 11.1 weeks
Cortes et al64 11 of 14 3148 ($70% M) 55–65 Mo: Early mobilization: sitting on bed/chair, walking,  
moving legs, climbing stairs, any movement out  
of bed, dangling legs, progressive activity while  
in hospital; settings descriptions: CCU,  
hospital wards, in-hospital
Jolliffe et al66 32 8440 (majority M) 55 Mo: AT: walking, running, cycling, skipping, swimming, 
stairs, and rowing; Fr: 1–5×/week; I: 70%–85%  
HRmax or predicted HRmax, other 75% max work 
capacity; T: 20–60 minutes; D: 4 weeks to 30 months 
Mo: RT: strengthening exercises for U/E and L/E;  
Fr: 3×/week; I: Target HR 85% HRmax;  
T: 60 minutes; D: 12 weeks
Clark et al62 41 of 63 8460 of 21295 
(majority M)
Mean 49–71 AT, RT: no details on intervention
Cornish et al63 2 of 7 120 of 213 57 ± 14–71.5 ± 7.8 Mo: AT: interval training: aerobic dance movements,  
upper/lower body exercises, cycle ergometer, or 
treadmill walking/running; Fr: 2–3×/week; I: 3 intervals 
of 5–10 minutes at RPE 15–18 in one study and 3 
minutes at 60%–70% HRmax + 4 minutes at 90%–95% 
HRmax in another; T: 50–60 minutes; D: 16–26 weeks
(Continued)
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Table 3 (Continued)
Author RCTs n (% M or F) Age (years) Characteristics of exercise intervention
Oliveira et al67 4 of 11 126 most ,60 Mo: RT: free weights in one study, NR in others;  
I: 40%–60% MVC or 50%–80% 1 RM; D: 10 weeks  
to 6 months; Other details NR
PVD
Watson et al69 16 of 22 783 of 1200 
(.50% M)
45–89 Mo: AT, RT: polestriding, cycling, and U/E and L/E  
exercises. Fr: 2–7×/week; T: 30–120 minutes;  
D: 3–12 months
Wind and  
Koelemay70
10 of 15 625 of 761 
(.50% M)
60–76 Mo: AT: crank exercise, walking, others not  
detailed. Fr: 2–3×/week; T: 30–60 minutes;  
D: 12–26 week except one study was 104 weeks
Hypertension
Dickinson et al73 21 of 105 1518 of 6805 
(∼57% M)
52 (30–67) Mo: AT: brisk walking, jogging, cycling; Fr: 3–5×/week; 
T: 30–60 minutes; D: 8–52 week (median 12). 
2 trials received RT, but details NR; 1 trial offered 
advice to participants
Cornelissen  
and Fagard72
28 of 72 492 in exercise  
group
52.7 ± 11.8 Mo: AT: walking, jogging, running, cycling;  
Fr: 2–7×/week (median 3); I: 30%–87% HRR  
(median 65); T: 25–60 minutes (median 40);  
D: 4–52 weeks (median 12)
Whelton et al74 15 of 54 872 (majority M) Mean 40–69 
Range 18–86
Mo: AT: biking, walking, jogging; Fr: 1–7×/week;  
I: 40%–70% VO2 max, 60%–85% HRmax, 40%–70%  
Wmax; T: 20–60 minutes; D: 3–26 weeks
Kelley et al71 47 2543 
.50% M
48 Mo: AT: walking, jogging, cycling, aerobic dance,  
and swimming; Fr: 1–5×/week; I: 45%–86% VO2 max;  
T: 15–60 minutes; D: 360–9360 minutes
Obesity
Shaw et al76 4 of 41 440 of 3476  
(majority M)
30–64 Mo: AT: walking/jogging, circuit training;  
Fr: 2–3×/week; I: 60%–80% HRmax;  
T: 30–60 minutes; D: 26–52 weeks
Witham  
and Avenell75
2 of 9 173 (100% F) 60 Mo: supervised AT, no details; Fr: 3×/week;  
I: aiming for 70% VO2 max; T: NR; D: 3 months; 
Transition to home: exercise 4×/week plus  
weekly supervised exercise
OA
Devos-Comby  
et al79
16 2154 Mean 65.8,  
range 29–89
Mo: AT + RT: knee muscles strength training,  
low/medium intensity exercise, and light physical  
activity (walking, aerobic exercise, balance or flexibility 
exercises); Fr: 2–5×/week (sometimes 2×/day);  
I: AT: 50%–85% HRR, RT: 6 set × 5 max contraction  
(others NR); T: 20 minutes – 1.5 hour;  
D: 4–12 weeks (different follow-up periods)
Lange et al80 18 2723 Range 55–74 Mo: RT: dynamic or isotonic training mainly targeting 
the quadriceps using resistance machines, free weights, 
or Theraband; Fr: 2–7×/week; I: light to maximal;  
T: 10–60 minutes, 5–12 reps, 1–10 sets (most 3 sets); 
D: 1–30 months
Ottawa Panel77 26 2486 .18 Mo: AT: walking or cycle ergometer; RT: strengthening 
(eg, isometric, isotonic, isokinetic, eccentric, concentric, 
aerobic), general physical activity, combination of 
exercises; Fr: 1×/week–10×/day (depends on phase);  
I: AT: 50%–70% HRR when described, RT: variable.  
T: 5 minutes–1.5 hours; D: 4 weeks–18 months
Brosseau et al78 9 of 12 1363 57–69.4 Mo: AT: walking, stationary bike; Fr: 1–4 ×/week;  
I: 50%–85% HRR or 60%–80% HRmax. T: 30–90 
minutes when reported; D: 5–12 weeks. Some changed 
to home-based program up to 15 months. Some 
studies included strengthening exercises
(Continued)
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Table 3 (Continued)
Author RCTs n (% M or F) Age (years) Characteristics of exercise intervention
Pelland et al81 17  
(plus 4 CCTs)
2325 Range 55.0–74.6 Mo: ROM exercises, low intensity walking on treadmill, 
RT: quadriceps, hamstrings, and hip abduction 
strengthening, stationary bike; Fr: most 2–3×/week, 
range: 1×/week–2×/day; I: variable; T: 15–40 minutes, 
3–9 exercises, 6–20 reps, 1–4 sets;  
D: 4 week–15 months
Osteoporosis
Li et al83 5 groups in  
4 papers
256 (100% F) NR Mo: RT or combined stretch/strength/balance 
programs: strengthening of extremities and trunk  
(1 study), “agility” training (1 study), combined exercise 
(stretching, strengthening, balance, posture) (2 studies), 
trunk flexor/extensor strengthening (1 study);  
Fr: 3 studies 2 days/week, 1 study 7 days/week; I: NR;  
T: 40–60 minutes; D: 10–25 weeks
De Kam et al82 28 1707, some reports  
used the same  
subjects
Mean 57–82 Mo: fast walking; aerobic exercise; weight-bearing 
aerobic exercise; strengthening exercises; balance 
exercises; posture and gait exercises; trunk extensor 
exercises; heel drops with impact; heel drops with 
no impact; whole body vibration; jumping; agility 
training including ball games, relay races and obstacle 
courses; tai chi; home-based walking, strengthening and 
stretching; Fr: 3–7×/week; I: not described – only one 
study described progression by increasing step count 
by 30%; T: 4–90 minutes; D: 10–104 weeks
Diabetes
Chudyk and  
Petrella85
30 of 34 NR NR Mo: AT; Fr: most 3×/week but range of  
1–7×/week; I: 50%–85% VO2 max or 35%–85%  
HRmax; T: 40–75 minutes; D: 2–24 months. 
RT: variable
Umpierre et al90 23 of 47 1513 of 8538 Range of means  
52–69
Mo: AT, RT; Fr: 2–5×/week T: AT: 30–150 minutes/
week and RT: 9–27 sets; D: 12–52 weeks
Irvine and Taylor86 7 of 9 162 of 256 47–68 Mo: RT: free weights or weight machines;  
Fr: 2–3×/week; I: 55%–85% 1RM or to moderate  
on Borg; T: 8–15 reps, 1–3 sets, 5–10 exercises;  
D: 8–26 weeks
Thomas et al89 14 377 45–65 Mo: qi gong, RT, AT: cycle ergometer, walking cycling, 
skiing, swimming; Fr: 3–7×/week; I: AT: 50%–85% 
VO2 peak, 65%–75% HRR or 85% HRmax; T: 30–120 
minutes; if PRT, 2–3 sets of 10–12 reps;  
D: 8 weeks–1 year
Kelley and  
Kelley87
7 Both 40–75 Mo: AT: cycle ergometer, walking, jogging, cycling, 
swimming, skiing; Fr: 3–7×/week I: 60%–75% VO2 max; 
T: 30–75 minutes; D: 10–26 weeks
Snowling and  
Hopkins88
27 1003 55 ± 7 Mo: AT; Fr: 3–7×/week; I: 50%–85% VO2 max,  
HR 110–140 bpm, 40%–80% HRR; T: 30–120  
minutes; D: 6–104 weeks. 
Mo: RT; Fr: 3–5×/week; I: 50%–80% of 1 RM;  
T: 10–20 reps, 2–3 sets, 5–10 ex; D: 5–16 weeks
Boulé et al84 27 266 55.7 Mo: AT: continuous aerobic; walking, cycling, skiing 
jogging, rowing, Theraband; Fr: 3–6×/week; 60%–75%; 
I: VO2 max; T: 40–60 minutes; D: 8–52 weeks
HIV
O’Brien et al91 7 of 14 306 of 454 
(∼70% M)
18–58 Mo: AT: interval or continuous aerobic, walking, 
jogging, stair stepping, ski machine, stationary bike, 
cross country machine. Fr: 3×/week I: AT: usually 
50%–85% VO2 max and 60%–80% HRmax or RT: 
60%–80% 1 RM; T: 20–60 minutes, D: 5–24 weeks
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Table 3 (Continued)
Author RCTs n (% M or F) Age (years) Characteristics of exercise intervention
Depression/anxiety
Krogh et al93 13 272 17–85 Mo: AT, RT, AT + RT; Fr: 2–5×/week; D: 8–16 week;  
AT: I: 70%–80% HRmax, 50%–70% aerobic capacity;  
T: 30–60 minutes. RT: I: 80% RM; T: 20 minutes  
or 8 reps × 3 sets
Herring et al94 40 NR (59% F) 50 ± 10 Mo: AT, RT, AT+RT; Fr: 3 ± 1×/wk; I: variable;  
T: 42 ± 22; D: 16 ± 10 wk 
Mead et al96 23 of 25 640 $18 Mo: AT: running, treadmill walking or walking, 
stationary cycling; RT; Mixed: A + RT, qi gong exercises, 
individually tailored, tai chi; D: 10 days – 16 weeks
Rethorst et al95 58 2982 15–94 Mo: AT; Fr: 3–5×/week; I: moderate to high  
T: 20–60 minutes; Mo: RT; F: 2–3 × /week  
T: 20–60 minutes; Mo: A + RT; T: 20–90 minutes;  
D: acute – 52 week
Lawlor and  
Hopker92
11 of 14 479 (∼34% M) All ages Mo: AT: running, walking; Fr: 2–5×/week;  
T: 20–60 minutes; D: 4–12 week
Notes: In RCT columns, number of RCTs from total number of studies. In number of subject’s (n) columns, number of subjects that were analyzed and total number of 
participants.
Abbreviations: AECOPD, acute exacerbation of COPD; AT, aerobic training; D, duration of training program; Fr, frequency; HRR, heart rate reserve; I, intensity; L/E: 
Lower extremity; M, male; F, female; Mo, modality; mod, moderate; NR, not reported; RT, resistance training; T, session time; U/E, upper extremity; ROM, range of motion; 
SWT, shuttle walking test; PRT, progressive resistance training.
AT and RT of the extremities improved maximal exercise 
capacity, walk distance performance, and quality of life 
measures in outpatient COPD compared to a control group 
as described by a high quality SR with an AMSTAR score 
of 10.42 Whether people with mild-to-moderate COPD with 
AECOPD benefit from exercise training is equivocal, as sum-
marized by two SRs with AMSTAR scores of 5 and 8.40,44 
Exercise training that focused on RT improved leg strength 
and cycling endurance as described by one review with an 
AMSTAR of 8.43 Unsupported and supported arm exercise 
showed improvement in half of the studies evaluated by one 
SR.41 Home exercise demonstrated improvement in exercise 
capacity in all studies that assessed this attribute and half 
of the studies that assessed quality of life.45 Dyspnea was 
significantly improved by aerobic and resistance trainings 
in two reports.42,44
Walking and cycling were the most common AT whereas 
free weights and Theraband™ were the most common resis-
tance used during RT. Frequency of training ranged from 
twice weekly to twice daily. The intensity of aerobic training 
was either not described in the SRs or, in one report, was 
quantified as a percentage of walk test distance.45 RT intensity 
ranged from one-third of a (repetition maximum) RM to near 
maximal intensity for the number of repetitions. The time 
for each session varied between 30 and 120 minutes, or was 
defined in terms of repetitions and sets for RT.41,43 Durations 
of studies ranged between four weeks and 18 months. There 
was an obvious focus on AT and RT in the SRs, and no 
reports described the outcomes from balance or functional 
training in people with COPD.
Older adults
Overall, exercise training results in improved physical and 
functional performance for older adults, as demonstrated by 
seven SRs,46–52 although initial health status influenced both 
the ability to participate in certain programs as well as the 
outcomes of the training. Most SRs and many RCTs included 
a mix of RT, BT, and functional training rather than focusing 
on a single type of training. Thus, evidence for the most part 
is provided from multifaceted training rather than a singular 
approach. Many other aspects of the training varied widely, 
with a training frequency most often of two to three times a 
week, total duration that ranged from 2 to 104 weeks, and a 
variable intensity level (Table 3). SRs, which had AMSTAR 
scores ranging from 5 to 11, showed that mixed training 
improved balance47,49,52 and strength,47,51,52 reduced falls,48 and 
improved functional measures such as the 6-minute walk dis-
tance (6MWD).46,49,51,52 An SR that had a singular focus on RT 
with an AMSTAR of 11 showed widespread improvements in 
lower extremity strength, aerobic capacity, and several physical 
performance tests (Table 4).50 In addition, this SR provided evi-
dence that RT reduced the relative risk of death and pain.50
Heart failure
Six meta-analyses53–58 investigated the benefits of AT and/or 
RT in patients with chronic heart failure. Most of these papers 
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.
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n
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n
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D
i
j
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r
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s
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t
 
a
l
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I
n
s
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t
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o
n
a
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e
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r
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A
T
,
 
R
T
,
 
b
a
l
a
n
c
e
 
 
a
n
d
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u
n
c
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i
o
n
a
l
 
 
t
r
a
i
n
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n
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S
t
r
e
n
g
t
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i
n
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f
 
9
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t
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d
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e
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D
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y
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o
g
i
c
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f
u
n
c
t
i
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n
/
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r
c
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d
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e
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l
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e
c
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p
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n
t
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e
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t
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p
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c
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c
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c
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.
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c
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1
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5
/
M
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3
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n
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t
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e
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1
3
/
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1
/
M
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.
9
1
 
m
L
/
k
g
/
m
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;
 
6
M
W
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1
5
/
5
9
9
/
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D
 
4
6
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2
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H
R
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u
r
i
n
g
 
m
a
x
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m
a
l
 
e
x
e
r
c
i
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1
8
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M
D
 
3
.
5
 
b
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B
P
 
d
u
r
i
n
g
 
m
a
x
i
m
a
l
 
e
x
e
r
c
i
s
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:
 
1
0
/
3
8
2
/
M
D
 
5
.
4
 
m
m
H
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Q
o
L
:
 
9
/
4
6
3
/
M
D
 
−
9
.
7
 
p
o
i
n
t
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E
n
d
-
d
i
a
s
t
o
l
i
c
 
v
o
l
u
m
e
 
a
t
 
r
e
s
t
:
 
9
/
5
2
7
/
W
D
 
−
3
.
1
3
 
m
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;
 
C
a
r
d
i
a
c
 
o
u
t
p
u
t
 
d
u
r
i
n
g
 
m
a
x
i
m
a
l
 
e
x
e
r
c
i
s
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3
/
1
0
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/
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2
.
5
1
 
L
/
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S
p
r
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i
t
 
e
t
 
a
l
6
1
H
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s
e
v
e
r
i
t
y
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t
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c
r
i
t
e
r
i
o
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f
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r
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n
c
l
u
s
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R
T
M
e
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n
 
p
e
a
k
 
i
s
o
t
o
n
i
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r
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n
g
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p
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r
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o
w
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1
6
/
3
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s
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e
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n
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2
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m
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r
o
v
e
m
e
n
t
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C
a
h
a
l
i
n
 
e
t
 
a
l
6
0
H
F
,
 
s
e
v
e
r
i
t
y
 
n
o
t
 
 
a
 
c
r
i
t
e
r
i
o
n
R
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,
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i
t
h
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r
t
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r
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n
g
 
b
u
r
s
t
s
 
o
f
 
A
T
M
u
s
c
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c
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r
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d
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p
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c
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f
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d
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L
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c
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R
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c
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t
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f
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m
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h
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T
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p
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c
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c
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t
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c
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t
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n
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n
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l
i
n
-
s
t
i
m
u
l
a
t
e
d
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p
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p
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p
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c
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s
c
l
e
 
e
n
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r
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n
c
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o
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,
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r
t
 
r
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d
u
r
i
n
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e
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r
c
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d
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r
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m
 
b
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d
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p
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p
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e
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b
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i
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p
e
r
c
u
t
a
n
e
o
u
s
 
 
i
n
t
e
r
v
e
n
t
i
o
n
)
A
T
 
(
m
a
j
o
r
i
t
y
)
,
 
R
T
V
O
2
 
m
a
x
 
f
o
r
 
a
e
r
o
b
i
c
 
t
r
a
i
n
i
n
g
:
 
1
5
/
8
0
7
/
S
M
D
 
0
.
6
7
 
m
L
/
k
g
/
m
i
n
 
 
[
0
.
3
9
,
 
0
.
9
4
]
;
 
L
o
n
g
e
r
 
e
x
e
r
c
i
s
e
 
t
r
a
i
n
i
n
g
 
p
e
r
i
o
d
 
(
.
6
 
m
o
n
t
h
s
)
 
s
t
a
r
t
i
n
g
 
s
o
o
n
 
a
f
t
e
r
 
a
 
c
a
r
d
i
a
c
 
e
v
e
n
t
 
(
,
3
 
m
o
n
t
h
s
)
 
h
a
d
 
 
a
 
s
i
g
n
i
fi
c
a
n
t
 
e
f
f
e
c
t
 
o
n
 
V
O
2
 
m
a
x
 
i
n
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
C
H
D
:
 
 
7
/
4
0
6
/
S
M
D
 
0
.
9
4
 
m
L
/
k
g
/
m
i
n
 
[
0
.
3
8
,
 
1
.
5
0
]
 
a
n
d
 
1
1
/
6
4
7
/
S
M
D
 
 
0
.
7
7
 
m
L
/
k
g
/
m
i
n
 
[
0
.
4
4
,
 
1
.
1
0
,
 
P
 
,
 
0
.
0
0
1
]
 
r
e
s
p
e
c
t
i
v
e
l
y
C
o
r
t
e
s
 
e
t
 
a
l
6
4
A
c
u
t
e
 
m
y
o
c
a
r
d
i
a
l
 
 
i
n
f
a
r
c
t
i
o
n
I
n
 
h
o
s
p
i
t
a
l
 
e
a
r
l
y
 
 
m
o
b
i
l
i
z
a
t
i
o
n
T
r
e
n
d
 
t
o
w
a
r
d
s
 
d
e
c
r
e
a
s
e
d
 
t
o
t
a
l
 
m
o
r
t
a
l
i
t
y
 
a
n
d
 
n
o
n
-
f
a
t
a
l
 
 
r
e
-
i
n
f
a
r
c
t
i
o
n
,
 
b
u
t
 
n
.
s
J
o
l
l
i
f
f
e
 
e
t
 
a
l
6
6
C
o
r
o
n
a
r
y
 
h
e
a
r
t
 
d
i
s
e
a
s
e
A
T
 
(
m
a
j
o
r
i
t
y
)
,
 
R
T
C
o
m
p
r
e
h
e
n
s
i
v
e
 
c
a
r
d
i
a
c
 
r
e
h
a
b
i
l
i
t
a
t
i
o
n
:
 
T
o
t
a
l
 
c
a
r
d
i
a
c
 
d
e
a
t
h
:
 
2
2
/
2
9
0
3
/
O
R
 
0
.
7
5
 
[
0
.
5
9
,
 
0
.
9
7
]
;
 
T
o
t
a
l
 
c
h
o
l
e
s
t
e
r
o
l
:
 
9
/
1
1
9
8
,
 
−
0
.
6
5
 
m
m
o
l
/
L
 
[
−
0
.
7
5
,
 
−
0
.
5
5
]
;
 
L
D
L
 
c
h
o
l
e
s
t
e
r
o
l
:
 
6
/
7
2
8
,
 
−
0
.
6
1
 
m
m
o
l
/
L
 
[
−
0
.
7
3
,
 
−
0
.
5
0
]
;
 
T
r
i
g
l
y
c
e
r
i
d
e
s
:
 
S
m
a
l
l
 
b
u
t
 
s
i
g
n
i
fi
c
a
n
t
 
r
e
d
u
c
t
i
o
n
 
(
n
o
 
n
u
m
b
e
r
s
)
 
E
x
e
r
c
i
s
e
 
o
n
l
y
:
 
T
o
t
a
l
 
c
a
r
d
i
a
c
 
d
e
a
t
h
:
 
8
/
2
3
1
2
/
O
R
 
0
.
7
0
 
[
0
.
5
1
,
 
0
.
9
4
]
;
 
T
o
t
a
l
 
m
o
r
t
a
l
i
t
y
:
 
1
2
/
2
5
8
2
/
O
R
 
0
.
7
4
 
[
0
.
5
6
,
 
0
.
9
8
]
C
l
a
r
k
 
e
t
 
a
l
6
2
I
s
c
h
e
m
i
c
 
h
e
a
r
t
 
d
i
s
e
a
s
e
A
T
,
 
R
T
 
(
n
o
 
d
e
t
a
i
l
s
)
P
r
o
g
r
a
m
 
w
i
t
h
 
e
x
e
r
c
i
s
e
:
 
R
e
c
u
r
r
e
n
t
 
M
I
:
 
1
2
/
3
9
9
7
/
R
R
 
0
.
6
2
 
[
0
.
4
4
,
 
0
.
8
7
]
 
E
x
e
r
c
i
s
e
 
o
n
l
y
:
 
M
o
r
t
a
l
i
t
y
:
 
1
1
/
2
2
8
5
/
R
R
 
0
.
7
2
 
[
0
.
5
4
,
 
0
.
9
5
]
C
o
r
n
i
s
h
 
e
t
 
a
l
6
3
I
s
c
h
e
m
i
c
 
C
A
D
 
(
n
a
r
r
a
t
i
v
e
 
r
e
v
i
e
w
)
A
T
 
(
i
n
t
e
r
v
a
l
 
t
r
a
i
n
i
n
g
)
E
x
e
r
c
i
s
e
 
c
a
p
a
c
i
t
y
:
 
2
 
s
t
u
d
i
e
s
 
(
o
f
 
2
)
 
s
h
o
w
e
d
 
↑
 
i
n
 
e
i
t
h
e
r
 
 
6
 
M
W
D
,
 
c
y
c
l
e
 
t
e
s
t
 
t
i
m
e
,
 
V
O
2
 
m
a
x
,
 
t
i
m
e
 
t
o
 
f
a
t
i
g
u
e
 
 
a
n
d
 
H
R
r
e
s
t
,
 
w
h
i
l
e
 
b
o
t
h
 
s
h
o
w
e
d
 
i
n
c
r
e
a
s
e
 
i
n
 
w
o
r
k
l
o
a
d
O
l
i
v
e
i
r
a
 
e
t
 
a
l
6
7
P
o
s
t
-
M
I
,
 
C
A
B
G
 
(
n
a
r
r
a
t
i
v
e
 
r
e
v
i
e
w
)
R
T
E
x
e
r
c
i
s
e
 
c
a
p
a
c
i
t
y
:
 
2
 
o
f
 
2
 
s
t
u
d
i
e
s
 
s
h
o
w
e
d
 
↑
 
i
n
 
6
M
W
D
;
 
M
u
s
c
l
e
 
s
t
r
e
n
g
t
h
:
 
2
 
s
t
u
d
i
e
s
 
(
o
f
 
2
)
 
s
h
o
w
e
d
 
↑
 
i
n
 
m
u
s
c
l
e
 
 
s
t
r
e
n
g
t
h
(
C
o
n
t
i
n
u
e
d
)
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T
a
b
l
e
 
4
 
(
C
o
n
t
i
n
u
e
d
)
A
u
t
h
o
r
C
o
n
d
i
t
i
o
n
 
a
n
d
 
s
e
v
e
r
i
t
y
T
y
p
e
 
o
f
 
t
r
a
i
n
i
n
g
:
G
e
n
e
r
i
c
 
fi
t
n
e
s
s
,
 
q
u
a
l
i
t
y
 
o
f
 
l
i
f
e
 
 
a
n
d
 
f
u
n
c
t
i
o
n
a
l
 
o
u
t
c
o
m
e
s
 
#
 
R
C
T
s
/
n
/
d
i
f
f
e
r
e
n
c
e
 
 
[
9
5
%
 
c
o
n
fi
d
e
n
c
e
 
i
n
t
e
r
v
a
l
s
]
D
i
s
e
a
s
e
 
s
p
e
c
i
fi
c
 
fi
t
n
e
s
s
,
 
c
o
n
t
r
o
l
 
 
a
n
d
 
p
r
e
v
e
n
t
i
o
n
 
o
u
t
c
o
m
e
s
 
#
 
t
r
i
a
l
s
/
n
/
d
i
f
f
e
r
e
n
c
e
 
 
[
9
5
%
 
c
o
n
fi
d
e
n
c
e
 
i
n
t
e
r
v
a
l
s
]
W
a
t
s
o
n
 
e
t
 
a
l
6
9
P
V
D
A
T
,
 
R
T
M
a
x
i
m
a
l
 
w
a
l
k
i
n
g
 
t
i
m
e
:
 
7
/
2
5
5
/
 
M
D
:
 
5
.
1
 
[
4
.
5
,
 
5
.
7
]
;
 
M
a
x
i
m
a
l
 
w
a
l
k
i
n
g
 
d
i
s
t
a
n
c
e
:
 
6
/
3
9
1
,
 
M
D
:
 
1
1
3
.
2
0
 
M
 
 
[
9
5
.
0
,
 
1
3
1
.
4
]
P
a
i
n
-
f
r
e
e
 
w
a
l
k
i
n
g
 
t
i
m
e
 
t
i
m
e
:
 
3
/
1
5
0
,
 
M
D
:
 
2
.
9
 
m
i
n
 
[
2
.
5
,
 
3
.
3
]
;
 
P
a
i
n
-
f
r
e
e
 
w
a
l
k
i
n
g
 
d
i
s
t
a
n
c
e
:
 
6
/
3
2
2
,
 
M
D
:
 
8
2
.
2
 
M
 
[
7
1
.
7
,
 
9
2
.
7
]
W
i
n
d
 
a
n
d
 
K
o
e
l
e
m
a
y
7
0
P
V
D
A
T
W
a
l
k
i
n
g
 
d
i
s
t
a
n
c
e
:
 
9
/
4
9
9
,
 
W
M
D
:
 
1
5
5
.
8
 
M
 
[
8
0
.
8
,
 
2
3
0
.
7
]
P
a
i
n
 
f
r
e
e
 
w
a
l
k
i
n
g
 
d
i
s
t
a
n
c
e
:
 
 
8
/
4
0
9
,
 
W
M
D
:
 
8
1
.
3
 
M
 
[
3
5
.
5
,
 
1
2
7
.
1
]
D
i
c
k
i
n
s
o
n
 
e
t
 
a
l
7
3
H
y
p
e
r
t
e
n
s
i
o
n
A
T
S
B
P
:
 
2
1
/
1
3
4
6
/
M
D
:
 
−
6
.
1
 
m
m
H
g
 
[
−
1
0
.
1
,
 
−
2
.
1
;
 
I
2
 
=
 
8
7
%
]
;
 
D
B
P
:
 
2
1
/
1
3
4
6
/
M
D
:
 
−
3
.
0
 
m
m
H
g
 
[
−
4
.
9
,
 
−
1
.
1
;
 
I
2
 
=
 
7
4
%
]
C
o
r
n
e
l
i
s
s
e
n
 
a
n
d
 
 
F
a
g
a
r
d
7
2
H
y
p
e
r
t
e
n
s
i
o
n
A
T
V
O
2
 
m
a
x
:
 
1
7
/
2
7
9
/
W
M
D
 
4
.
4
 
m
L
/
k
g
/
m
i
n
 
[
3
.
7
,
 
5
.
1
]
;
 
H
R
:
 
2
3
/
3
4
0
/
W
M
D
 
−
4
.
5
 
b
p
m
 
[
−
6
.
5
;
 
−
2
.
6
]
;
 
S
B
P
:
 
3
0
/
4
9
2
/
W
M
D
 
−
6
.
9
 
m
m
H
g
 
[
−
9
.
1
;
 
−
4
.
6
]
;
 
D
B
P
:
 
3
0
/
4
9
2
/
W
M
D
 
−
4
.
9
 
m
m
H
g
 
[
−
6
.
5
;
 
−
3
.
3
]
.
W
h
e
l
t
o
n
 
e
t
 
a
l
7
4
H
y
p
e
r
t
e
n
s
i
o
n
A
T
S
B
P
:
 
1
5
/
N
R
/
E
S
 
−
4
.
9
4
 
m
m
H
g
 
[
−
7
.
1
7
,
 
−
2
.
7
0
]
;
 
D
B
P
:
 
1
3
/
N
R
/
E
S
 
−
3
.
7
3
 
m
m
H
g
 
[
−
5
.
6
9
,
 
−
1
.
7
7
]
K
e
l
l
e
y
 
e
t
 
a
l
7
1
H
y
p
e
r
t
e
n
s
i
o
n
A
T
S
B
P
:
 
−
6
 
m
m
H
g
 
[
−
8
,
 
−
3
]
 
(
n
u
m
b
e
r
 
o
f
 
t
r
i
a
l
s
/
s
u
b
j
e
c
t
s
 
N
R
)
;
 
D
B
P
:
 
−
5
 
m
m
H
g
 
[
−
7
,
 
−
3
]
 
(
n
u
m
b
e
r
 
o
f
 
t
r
i
a
l
s
/
s
u
b
j
e
c
t
s
 
N
R
)
S
h
a
w
 
e
t
 
a
l
7
6
O
b
e
s
i
t
y
A
T
D
B
P
:
 
2
/
2
5
9
/
W
M
D
 
-
2
.
0
9
 
m
m
H
g
 
[
−
3
.
6
8
,
 
−
0
.
5
1
]
T
r
i
g
l
y
c
e
r
i
d
e
s
:
 
3
/
3
4
8
/
W
M
D
 
−
0
.
1
8
 
m
m
o
l
/
l
 
[
−
0
.
3
1
,
 
−
0
.
0
5
]
;
 
F
a
s
t
i
n
g
 
g
l
u
c
o
s
e
:
 
2
/
2
7
3
/
W
M
D
 
−
0
.
1
7
 
m
m
o
l
/
l
 
[
−
0
.
3
0
,
 
−
0
.
0
5
]
;
 
H
D
L
:
 
3
/
3
4
8
/
W
M
D
 
0
.
0
6
 
m
m
o
l
/
l
 
[
0
.
0
3
,
 
0
.
0
9
]
W
i
t
h
a
m
 
a
n
d
 
 
A
v
e
n
e
l
l
7
5
O
b
e
s
e
 
p
o
s
t
m
e
n
o
p
a
u
s
a
l
 
 
w
o
m
e
n
A
T
,
 
R
T
V
O
2
 
m
a
x
:
 
i
n
c
r
e
a
s
e
 
b
y
 
1
1
.
7
%
 
i
n
 
t
h
e
 
i
n
t
e
r
v
e
n
t
i
o
n
 
g
r
o
u
p
 
 
a
n
d
 
0
.
7
%
 
i
n
 
t
h
e
 
c
o
n
t
r
o
l
 
g
r
o
u
p
 
a
t
 
1
2
 
m
o
n
t
h
s
 
(
P
 
,
 
0
.
0
0
1
)
D
e
v
o
s
-
C
o
m
b
y
 
 
e
t
 
a
l
7
9
O
A
A
T
,
 
R
T
,
 
a
n
d
 
 
b
a
l
a
n
c
e
D
i
r
e
c
t
 
m
e
a
s
u
r
e
s
 
o
f
 
i
m
p
a
i
r
m
e
n
t
 
(
w
a
l
k
i
n
g
 
d
i
s
t
a
n
c
e
 
t
e
s
t
,
 
 
t
i
m
e
d
 
c
h
a
i
r
 
r
i
s
e
,
 
t
i
m
e
 
g
e
t
t
i
n
g
 
o
u
t
 
o
f
 
a
 
c
a
r
,
 
b
a
l
a
n
c
e
 
t
e
s
t
s
,
 
 
o
r
 
g
a
i
t
)
:
 
1
1
/
7
4
0
/
 
S
E
S
 
0
.
1
5
 
[
0
.
0
8
,
 
0
.
2
3
]
C
o
m
b
i
n
e
d
 
p
h
y
s
i
c
a
l
 
o
u
t
c
o
m
e
s
 
(
S
c
a
l
e
s
 
o
f
 
p
h
y
s
i
c
a
l
 
d
i
s
a
b
i
l
i
t
y
,
 
d
i
s
c
o
m
f
o
r
t
,
 
p
a
i
n
,
 
f
u
n
c
t
i
o
n
,
 
m
o
b
i
l
i
t
y
 
i
e
,
 
A
I
M
S
)
:
 
 
1
2
/
8
0
8
/
S
E
S
:
 
0
.
2
9
 
[
0
.
2
3
,
 
0
.
3
6
]
.
L
a
n
g
e
 
e
t
 
a
l
8
0
K
n
e
e
 
O
A
R
T
S
t
r
e
n
g
t
h
:
 
↑
 
i
n
 
9
 
o
f
 
1
4
 
s
t
u
d
i
e
s
;
 
M
a
x
i
m
a
l
 
g
a
i
t
 
s
p
e
e
d
:
 
 
↑
 
i
n
 
4
 
o
f
 
4
 
s
t
u
d
i
e
s
;
 
M
a
x
i
m
a
l
 
s
t
a
i
r
 
c
l
i
m
b
/
d
e
s
c
e
n
t
:
 
 
↑
 
i
n
 
3
 
o
f
 
5
 
s
t
u
d
i
e
s
P
a
i
n
:
 
↑
 
i
n
 
1
0
 
o
f
 
1
8
 
s
t
u
d
i
e
s
;
 
P
h
y
s
i
c
a
l
 
d
i
s
a
b
i
l
i
t
y
:
 
↑
 
i
n
 
1
1
 
o
f
 
1
4
 
s
t
u
d
i
e
s
;
 
P
h
y
s
i
c
a
l
 
s
e
l
f
 
e
f
fi
c
a
c
y
:
 
↑
 
i
n
 
2
 
o
f
 
2
 
s
t
u
d
i
e
s
O
t
t
a
w
a
 
P
a
n
e
l
7
7
O
A
A
T
,
 
R
T
S
t
r
e
n
g
t
h
,
 
a
e
r
o
b
i
c
 
c
a
p
a
c
i
t
y
,
 
a
n
d
 
f
u
n
c
t
i
o
n
a
l
 
s
t
a
t
u
s
:
 
d
i
f
f
e
r
e
n
t
 
 
l
e
v
e
l
s
 
o
f
 
e
v
i
d
e
n
c
e
 
s
u
p
p
o
r
t
 
v
a
r
i
o
u
s
 
t
y
p
e
s
 
o
f
 
s
t
r
e
n
g
t
h
e
n
i
n
g
,
 
 
m
o
b
i
l
i
t
y
 
a
n
d
 
fl
e
x
i
b
i
l
i
t
y
 
e
x
e
r
c
i
s
e
s
 
b
a
s
e
d
 
o
n
 
R
C
T
s
 
b
u
t
 
n
o
 
 
s
y
n
t
h
e
s
i
s
 
o
f
 
d
a
t
a
 
f
r
o
m
 
m
o
r
e
 
t
h
a
n
 
o
n
e
 
R
C
T
 
w
a
s
 
p
r
o
v
i
d
e
d
P
a
i
n
:
 
d
i
f
f
e
r
e
n
t
 
l
e
v
e
l
s
 
o
f
 
e
v
i
d
e
n
c
e
 
f
r
o
m
 
R
C
T
s
 
s
h
o
w
 
t
h
a
t
 
 
d
i
f
f
e
r
e
n
t
 
t
y
p
e
s
 
o
f
 
e
x
e
r
c
i
s
e
 
d
e
c
r
e
a
s
e
 
p
a
i
n
.
 
N
o
 
s
y
n
t
h
e
s
i
s
 
 
o
f
 
d
a
t
a
 
f
r
o
m
 
m
o
r
e
 
t
h
a
n
 
o
n
e
 
R
C
T
 
w
a
s
 
p
r
o
v
i
d
e
d
B
r
o
s
s
e
a
u
 
e
t
 
a
l
7
8
O
A
A
T
A
e
r
o
b
i
c
 
c
a
p
a
c
i
t
y
,
 
t
i
m
e
d
 
w
a
l
k
 
d
i
s
t
a
n
c
e
,
 
w
a
l
k
 
v
e
l
o
c
i
t
y
:
 
↑
 
i
n
 
 
R
C
T
s
 
b
u
t
 
n
o
 
s
y
n
t
h
e
s
i
s
 
o
f
 
d
a
t
a
 
f
r
o
m
 
m
o
r
e
 
t
h
a
n
 
o
n
e
 
 
R
C
T
 
w
a
s
 
p
r
o
v
i
d
e
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had AMSTAR scores ranging from 6 to 8, although one57 
had a score of 3. Based on these papers, it can be concluded 
that AT and RT significantly improved numerous cardio-
pulmonary exercise outcomes, including increasing VO2 
max, 6MWD, maximal workload, and anaerobic threshold. 
It also improved several cardiac system factors, including 
increasing the heart rate and cardiac output during maximal 
exercise, improving left ventricular ejection fraction, and the 
end-diastolic and end-systolic ventricular volume. Two meta-
analyses also reported that exercise significantly improved 
quality of life in these patients.55,58
There were no meta-analyses that investigated the role 
of AT and/or RT on muscle strength or endurance. Three 
reviews without meta-analyses investigated the benefits of 
exercise on a large number of outcomes, including several 
that are specific to muscle performance.59–61 Exercise 
improved upper and lower extremity strength and muscle 
endurance, increased oxidative enzyme activity in the quad-
riceps muscle, and increased forearm blood flow. However, 
these results must be interpreted with caution as these reports 
were SRs without meta-analyses, and the AMSTAR scores 
were relatively low (2 to 6), with few details quantifying the 
magnitude of the effect.
The AT was relatively consistent across all the studies, in 
terms of frequency, mode, and intensity. Subjects exercised 
2–7 days per week, with most trials within each SR provid-
ing the exercise intervention for 3 days per week. Cycle 
ergometry and treadmill walking were the most commonly 
used modalities. Most studies prescribed an AT intensity 
based on a maximal cardiopulmonary exercise test, with 
exercise intensities ranging from 50% to 80% of VO2 max. 
The time per session and the durations of the programs 
were very variable, ranging from 12 to 100 minutes and 
1 to 14 months, respectively. Where described, the resis-
tance training prescription tended to be based on 40% to 
80% of one RM.
Ischemic heart disease
Seven SRs investigated the benefits of early mobilization, 
anaerobic training, and/or RT in ischemic heart disease 
patients.62–68 The AMSTAR scores ranged from 3 to 10, with 
two reviews having a score of 3,63,67 and one a score of 5.68 
The remaining reviews had AMSTAR scores exceeding 8.
The study populations were predominantly male. There 
was variation in the specific type of intervention (both AT 
and RT), and differing endpoints were utilized to evaluate 
benefit and responses. Five reviews examined the effects 
of AT,62,63,65,66,68 three reported the effects of both AT and 
RT,62,66,68 one examined the sole effect of early in-hospital 
mobilization,64 and one examined the sole effect of RT.67 
Some work focused on reporting disease-specific outcomes 
(ie, recurrent myocardial infarction, cholesterol and trig-
lyceride levels, ejection fraction, and end-systolic and end-
diastolic volumes),62,64,65,66 while others studied indices of 
overall activity and fitness (ie, walking distance, maximal 
aerobic capacity, exercise duration, and muscle strength)63,67,68 
in these populations with ischemic heart disease. Quality of 
life and health care utilization were not studied or specifi-
cally reported, and significant variation was evident in the 
duration of follow-up.
Early in-hospital mobilization demonstrated nonsignifi-
cant trends towards decreased total mortality and nonfatal 
re-infarction.64 The results suggest that anaerobic and RT 
reduces the risk of total cardiac death, recurrent myocardial 
infarction, as well as cholesterol and triglyceride levels. 
Improvements were also demonstrated in peak oxygen 
uptake, exercise duration, exercise workload, and 6MWD. 
The findings suggest that benefits were greater when exercise 
programming was initiated soon after an ischemic event (as 
early as 1 week post-myocardial infarction), and when exer-
cise program duration exceeded either 3 or 6 months (rather 
than ,3 months).
Peripheral vascular disease
Exercise training significantly improved the walking distance 
and pain-free walking distance in patients with peripheral 
vascular disease (PVD) when compared to standard care 
as evidenced by two meta-analyses with relatively high 
AMSTAR scores of 9 and 7.69,70 Exercise training was gener-
ally supervised. The optimal intensity was not clear, although 
it was suggested that patients exercised until near maximal 
pain. The majority of the studies applied an exercise regimen 
of two to three times per week for 30–60 minutes, with these 
usually incorporating walking, leg exercises, or treadmill 
training. Some encouraged additional home exercise.
Hypertension
Exercise training (mainly aerobic exercise) significantly 
lowered the systolic (SBP) and diastolic blood pressure 
(DBP) in people with hypertension, as supported by four 
meta-analyses.71–74 Two of the SRs73,74 had AMSTAR scores 
of 8 of 11 while two others had scores of 7 and 4.71,72 VO2 
max increased significantly and resting heart rate (HR) 
decreased after exercise training.72 Exercise training also 
demonstrated significant improvement in cardiovascular risk 
factors as shown by an increase in high density lipoprotein 
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cholesterol, and decreases in glucose, insulin levels, and the 
homeostatic model assessment index (a measure of insulin 
resistance), despite the inclusion of normotensives in the 
analysis.72 Reductions were greater for SBP in African–
American individuals and for DBP in Asian individuals, but 
only a small number of trials were conducted in people of 
different ethnic backgrounds.74
A variety of study designs were included in the meta-
analyses, but the majority of the studies included training 
programs that involved mainly aerobic exercise (walking, 
jogging, cycling), usually three to five times per week, for 
30 to 60 minutes, at moderate intensity. According to two 
SRs there is no relationship between blood pressure (BP) 
response and training characteristics (intensity, frequency), 
except for a lesser BP reduction associated with a longer 
total trial duration, probably due to loss of compliance in 
long trials.72,74
Because aerobic exercise also showed positive effects in 
normotensives, these data suggest that aerobic exercise is an 
important strategy not only in treating high blood pressure, 
but could potentially be used as prophylaxis.74
Obesity
Data on the effect of physical activity on fitness outcomes 
in this population were limited. In post-menopausal obese 
women, an exercise-based program improved VO2 max as 
shown in one RCT reported by one SR.75 A Cochrane review 
with an AMSTAR score of 11 did not report the effect of 
physical activity on VO2 max but found a decrease in DBP, 
reduced triglycerides and glucose, and increased HDL 
levels.76 The majority of trials in the two SRs consisted of 
AT, usually two to three times per week, at 60%–80% of VO2 
max or HRmax, with different durations utilized.
Osteoarthritis
Results from the five SRs examining the effects of exercise 
on patients with knee or hip OA consistently show beneficial 
results for fitness levels and functional performance, though 
emphasis was primarily on disease-specific outcomes such as 
joint pain or physical dysfunction.77–81 AMSTAR scores were 
between 7 and 9, and most studies failed to report publication 
bias or conflicts of interest.
Isotonic RT targeting the quadriceps or hamstrings 
muscle groups was the most common exercise interven-
tion, though AT and range of motion exercises were also 
included. Control interventions primarily included patient 
education or usual care with no additional treatment. Most 
exercise interventions lasted 3–6 months, though some were 
as short as 4 weeks and as long as 24 months. Some studies 
required daily exercise, while others included only two or 
three sessions per week. Individual sessions were typically 
45–60 minutes in length and complied with usual dosage 
characteristics for exercise in healthy populations (ie, three 
sets of ten repetitions for resistance training, and 50% to 80% 
of maximum heart rate for aerobic interventions).
Pain and physical function were consistently improved 
following exercise, but no particular type of exercise was 
found to be superior. Studies examining RT found improve-
ments in strength compared to control interventions,77,81 while 
studies examining the effects of AT found improvements in 
aerobic capacity, walking speed, and walking distance.77–80 
All studies found exercise to be a safe and feasible interven-
tion with minimal side effects for patients with OA.
Osteoporosis
Most of the SRs identified in this study investigated the 
benefits of exercise in the prevention of osteoporosis or 
osteopenia in healthy, pre- or post-menopausal women. 
Two SRs investigated the impact of exercise in women 
diagnosed with osteoporosis or osteopenia, and these had 
AMSTAR scores of 782 and 683, indicating moderate quality 
overall. One of these was an SR without a meta-analysis 
that evaluated the benefits of AT, RT, BT, and gait on 
numerous exercise- and disease-related outcomes. It was 
reported that exercise resulted in improvements in balance 
measures such as the timed-up-and-go, upper extremity 
strength, and walking velocity, as well a reduction in fall 
incidence and fall-related fractures.82 The other paper 
included a meta-analysis investigating the benefits of RT 
with or without balance exercise, and reported that exercise 
improved several quality-of-life domains including physical 
function, pain, and vitality.83
Type 2 diabetes mellitus
Seven meta-analyses investigated the benefits of RT and or 
AT in people with type 2 diabetes with AMSTAR scores 
that ranged from 6 to 11.84–90 Aerobic exercise improved 
VO2 max as evidenced by two SRs with AMSTAR scores 
of 6 and 11.84,89 Two SRs with AMSTAR scores of 6 also 
demonstrated reductions in SBP and DBP after AT, RT, or a 
combination of AT and RT.85,88 Strength measures improved 
after RT, as described by one SR with an AMSTAR of 7.86 
Glycosylated hemoglobin (HbA1c), a measure of blood sugar 
levels, was the most consistent outcome reported in all of 
the included SRs, with a reduction in this seen in all reviews 
regardless of the type of exercise training.84–90
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
313
Exercise in AECOPDInternational Journal of COPD 2012:7
The exercise interventions described were quite varied 
across the SRs. AT consisted of stationary cycling, outdoor 
cycling, walking, jogging, swimming, rowing, or skiing. RT 
was performed using a Theraband, free weights, or weight 
machines. AT intensity ranged 50%–85% of VO2 max, 
35%–85% of HRmax, or 40%–80% of HRR. RT inten-
sity ranged 50%–85% of one RM. The exercise sessions 
were between 30 and 120 minutes, and the duration of the 
program ranged from 5 to 52 weeks. The SRs primarily 
focused on the benefits of AT, RT, or a combination of these 
interventions. However, no studies focused on balance or 
functional training, or reported functional or quality-of-life 
outcomes.
HIV/AIDS
Interval and continuous AT improved VO2 max in patients 
living with HIV , as evidenced by a Cochrane review with an 
AMSTAR score of 10.91 This SR also described improved 
strength in five of the six studies that reported this measure. 
Additional benefits from exercise training include no change 
in the viral load, an increase in CD4 cell counts after interval 
AT, and improved Profile of Moods scores after AT. A sum-
mary of the interventions applied is shown in Table 3.
Depression
The five SRs relating to depression were moderate-to-high 
quality (AMSTAR 8-11).92–96 Exercise programs (AT, RT, or 
a combination of these) for people diagnosed with major or 
minor depression were found to result in improved scores 
on depression and mood, particularly in the short term.92,93 
Medium- to long-term effects were less clear.92,93 As a group 
of studies, the interventions were not well described. Most 
examined both AT, RT, and mixed AT plus RT, except one92 that 
focused on AT. The intensity of AT, if described, was moderate 
to high.93,95 Each session was 30 to 60 minutes in length, with 
these performed one to five times per week, and the duration 
of the programs was between 10 days and 52 weeks.
Discussion
This synthesis examined 58 systematic reviews of exercise 
training in people with AECOPD, COPD, or eleven chronic 
conditions commonly associated with COPD. Overall, this 
review provides Level 1A evidence97 that exercise training 
improves generic or disease-specific measures of fitness in 
several disease populations. Markers of endurance (aerobic 
capacity, 6MWD) were shown to improve in all conditions 
except depression, whereas strength was shown to improve 
in most conditions with the exception of PVD, hypertension, 
obesity, and depression. In addition, several studies in dif-
ferent disease populations also reported improvements in 
quality of life, function, control, or prevention outcomes. 
Depression was the only condition where SRs exclusively 
focused on disease-specific outcomes (measures of depres-
sion and anxiety).92–96 Exercise training also decreases the 
risk of mortality in older adults,50 and in those with COPD39 
or ischemic heart disease.66
Overwhelmingly, the most common types of training 
provided to people with all conditions reviewed were AT 
and RT. Balance and functional training were less commonly 
applied SRs of exercise training. However, these interventions 
had widespread application in most SRs that examined older 
adults,46–49,51,52 and in one SR that examined OA patients79 and 
one that examined osteoporosis patients.82
The quality of the SRs for most conditions was mod-
erate to excellent (.65%) as evaluated by AMSTAR 
scores. However, SRs that examined training outcomes 
in heart failure, ischemic heart disease, hypertension, and 
osteoporosis scored moderately poorly on the AMSTAR 
($51% but #61%). The listing of articles that were excluded 
from in the review was the most common item omitted from 
most SRs, which may have been due to page constraints. 
Even with this item excluded, the AMSTAR scores remained 
relatively low for heart failure (56%) whereas scores for the 
other conditions were $66%. In addition to the SR design 
and strength of AMSTAR scores, the number of participants 
and RCTs for each condition, including COPD, were large. 
These numbers further strengthen the foundation of evidence 
and recommendations for exercise training as an intervention 
that produces positive outcomes for COPD and commonly 
associated conditions.98
Although COPD patients often have one or more comor-
bidities, no information is available, on prescription param-
eters of exercise training for patients with multimorbidity.   
Training parameters from studies examining conditions that 
are common comorbidities might be applicable, however, 
consideration should be give to similarities of patient demo-
graphics and details of training, especially intensity. Given 
that the most common conditions associated with COPD are 
obesity (prevalence of 54%),26 osteoporosis (60%–70%)23 
and osteoarthritis (increasing prevalence to 40% at age 75)27 
(see Table 1), data from SRs describing these conditions may 
have the greatest relevance. The pertinence of these data is 
further strengthened by the similarity in age of participants 
from SRs that examined exercise training in people who 
were obese, had osteoporosis or osteoarthritis to those affected 
by COPD.  In contrast, subjects were somewhat younger in 
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some of the RCTs that examined obesity. Gender was mixed in 
all of these conditions, except in the case of the SRs on osteo-
porosis in which predominantly women were studied.82,83
The modalities of AT and RT for obesity, osteoporosis, 
and osteoarthritis were similar to those typically applied for 
COPD patients, although exercise training for these conditions 
utilized more diverse types of training. The intensity of AT 
appeared to be much higher for obese individuals and those 
with arthritis compared to that prescribed for COPD patients; 
intensity was commonly based on aerobic or HR parameters 
for the former compared to walk distance or dyspnea 
measures used in COPD patients. This raises the notion that 
a broader spectrum approach to exercise training in order to 
improve fitness in patients with COPD and comorbidities 
such as obesity, osteoporosis, and osteoarthritis may be 
effective. However, exercise training of the more complex 
COPD patient (with multiple comorbidities) may result in 
smaller gains of disease-specific outcomes due to the inability 
to achieve comparable AT and RT intensities (compared to 
those achieved in patients with a single condition). These 
issues merit further study.
Because obesity is a major cause of morbidity and a 
significant risk factor for other comorbidities such as heart 
disease and diabetes,26,75,76 SRs addressing exercise fitness 
outcomes other than body composition are needed in order 
to determine the overall impact of exercise training in this 
particular group. Although altering body composition may 
be the primary outcome for people who are obese, under-
standing the training and physiologic determinants to achieve 
that goal are essential; thus fitness outcomes such as aerobic 
capacity and strength measures should be reported in order to 
better evaluate the type and intensity of training that results 
in improvement. Moreover, it has also recently been dem-
onstrated that some obese COPD patients have better fitness 
outcomes than non-obese COPD patients.99 Determining how 
physical activity interventions can attenuate obesity, reduce 
cardiovascular risk factors, and improve overall fitness in 
people with COPD needs further attention.
Depression is a common comorbidity in COPD with 
estimates of prevalence ranging between 10% and 80%.25 
SRs that examined the effect of exercise on depression had 
participants with an age range similar to those with COPD, 
and the interventions were similar to many of the other con-
ditions in this review. A major contrast to the other SRs was 
that only disease-specific outcomes and no generic fitness 
measures were reported. All five SRs demonstrated significant 
decreases in depression or anxiety scores.92–96 These benefits 
were reported regardless of whether AT, RT, or a combination 
of AT and RT were applied. Of interest is the finding that the 
benefits decreased in response to longer training programs. 
More RCTs are needed to examine clinical sub-groups (minor, 
moderate, major depression), to compare different forms of 
exercise, and to clarify the appropriate dose/intensity of physi-
cal exercise in addition to the mechanism of improvement. 
Designing a training program that might result in gains related 
to self-efficacy would be very different from a regimen that 
requires improved aerobic fitness or an endorphin response 
to induce a therapeutic benefit. A better understanding of the 
type of depression most commonly experienced by COPD will 
also provide further insight into if and how exercise training 
can reduce the clinical severity of these two conditions.
Exercise training for older adults showed the greatest con-
trasts to interventions applied to COPD and other associated 
conditions in this review. This is especially important given 
that many individuals with COPD who present for health 
care interventions are 65 or older. Major foci appeared to 
be on balance and functional training rather than predeter-
mined intensities of AT or RT.46–49,51,52 In addition, frequently 
reported outcomes by the SRs on the elderly included bal-
ance/falls, and physical performance measures that were 
functional (ie, timed up-and-go, stair climbing) as opposed 
to more physiologic measures of strength and endurance. 
Exercise training for older adults may provide an excellent 
model to further broaden exercise prescription for COPD 
patients because, as with the elderly,48,49 people with COPD 
have a high relative risk of falls.100 In addition, the physical 
activity level of COPD patients is often comparable to much 
older, healthier adults. Thus, a greater focus on balance 
and functional training may not only reduce falls in COPD 
patients but might also result in greater gains in daily physical 
activity outside of pulmonary rehabilitation.101
Limitations
Although this synthesis of systematic reviews examined 
several conditions commonly associated with COPD, the 
participants within each of the SRs most often had a homo-
geneous presentation of the condition of interest. Only SRs 
of the elderly appeared to include participants with diverse 
and multiple morbidities. For this reason, it might be chal-
lenging to apply modalities in a sufficient dose in order to 
induce both generic and disease-specific benefits that address 
a complex patient with COPD and multimorbidities. The 
more functional approach of physical activity training, even 
in the frail elderly, did result in functional gains, and this 
approach may also prove to be beneficial to the AECOPD 
patients with multimorbidities.
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Many SRs included lengthy training programs but did 
not compare the benefits of shorter versus longer programs, 
with the exception of SRs that evaluated those with hyperten-
sion72,74 and depression.92,93 These SRs indicated a slightly 
diminished response with longer training programs, which 
may have resulted in a blunting of the physiologic benefits 
of exercise, decreased adherence to the exercise training 
program, or a continued onslaught of inciting factors that 
could no longer be countered by the benefits of exercise 
training.
Conclusions
In summary, this systematic review showed evidence of 
significant benefits from exercise training in AECOPD, 
COPD, and many conditions that are common comorbidities 
associated with COPD. Exercise training, primarily con-
sisting of AT and/or RT, leads to meaningful generic and 
disease-specific benefits in these conditions. Meta-analyses 
of endurance (aerobic or exercise capacity, 6MWD) were 
shown to improve in most conditions whereas meta-
analyses of strength were shown to improve in five of the 
13 conditions (that is, COPD, older adults, heart failure, 
ischemic heart disease, and diabetes). Additional research 
is required to determine the added benefit of RT plus AT in 
several conditions that are common comorbidities associ-
ated with COPD.
A broader approach to exercise and activity prescription 
in pulmonary rehabilitation for AECOPD may induce thera-
peutic benefits to ameliorate clinical sequelae associated with 
COPD and comorbidities. For example, BT and functional 
training, similar to that applied in older adults, could poten-
tially be very effective in improving functional outcomes 
including fall risk, and may have a greater impact on daily 
physical activity than recently demonstrated.101
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Appendix 1  
Search strategy for Medline Ovid
Most of the numbered items are entered as keywords or 
phrases in the search box on the main page of Medline 
OvidSP. However, some line items at the end of each concept 
(eg, line 7) are commands to combine previous items in a 
particular fashion for the main concept. Asterisks indicate 
truncated terms in Medline. As well, abbreviations (ie, adj3) 
can be used to link words together.
Similar search terms were used in all databases.   However, 
the preferred term could differ and the user needed to 
determine if the alternate term provided in a database was 
suitable. In addition, the manner of truncation, labeling for 
title or abstract, and combining of terms differed amongst 
databases.
Concept: COPD
  1.    lung diseases, obstructive/or exp pulmonary disease, 
chronic obstructive/or bronchitis, chronic/
  2.  exp Pulmonary Emphysema/
  3.    (obstruct* adj3 (pulmonary or lung* or airway* or air-
flow* or bronch* or respirat*)).ti,ab.
  4.    ((chronic airflow or chronic airway*) adj2 (disease* or 
disorder* or obstruct* or limitation*)).ti,ab.
  5.    (COPD or COAD or chronic bronchi* or emphysema* 
or hyperlucent lung*).ti,ab.
  6.  (chronic adj3 obstructive).ti,ab.
  7.  or/1–6
Concept: comorbidities
  8.    bronchial diseases/or asthma/or bronchial h  yperreactivity/
or bronchial spasm/or bronchiectasis/or exp bronchitis/
or bronchopneumonia/
  9.    (bronchial disease* or asthma* or bronchial asthma* or 
bronchial hyperreactivit* or bronchospasm*).ti,ab.
10.    (bronchiectas* or bronchitis or bronchopneumonia* or 
bronchial pneumonia*).ti,ab.
11.  exp Pneumonia/
12.    (pneumonia* or pneumoniti* or pulmonary inflam-
mation* or lung inflammation* or lobar pneumonia*).
ti,ab.
13.  Influenza, Human/
14.    ((influenza adj3 human*) or human flu or influenza* or 
grippe).ti,ab.
15.  respiratory insufficiency/
16.    (respiratory insufficiency or respiratory failure or respira-
tory depression).ti,ab.
17.    heart diseases/or arrhythmias, cardiac/or heart failure/
or myocardial ischemia/or myocardial infarction/or 
pulmonary heart disease/
18.    (arrythmia or arrhythmia or cardiac arrhythmia* or 
  cardiac dysrhythmia*).ti,ab.
19.    (heart failure or cardiac failure or myocardial failure or 
heart decompensation or myocardial infarction).ti,ab.
20.  (pulmonary heart disease* or cor pulmonale).ti,ab.
21.  Hypertension/
22.  (hypertension or high blood pressure).ti,ab.
23.  Diabetes Mellitus/
24.  (diabetes mellitus or diabetes).ti,ab.
25.  Obesity/or Overweight/
26.  (obesity or overweight).ti,ab.
27.  Sleep Apnea, Obstructive/
28.    (sleep apnea or obstructive sleep apnea or obstructive 
sleep apnea syndrome).ti,ab.
29.  Depression/
30.    (depression* or depressive symptoms or emotional 
depression*).ti,ab.
31.  Anxiety/
32.  (anxiet* or nervousness or anxious).ti,ab.
33.  Anemia/
34.  (anemia* or anaemia).ti,ab.
35.  Osteoporosis/
36.    (osteoporos#s or senile osteoporos#s or bone-loss*).
ti,ab.
37.  Osteoarthritis/
38.    (osteoarthritis or osteoarthritides or osteoarthros#s or 
degenerative arthritis).ti,ab.
39.  osteopenia.mp.
40.  exp aged/or frail elderly/
41.    (aged or elderly or frail elderly or frail elder* or frail 
older adult*).ti,ab.
42.  or/8–41
43.  7 or 42
Concept: hospitalized patients
44.  exp Inpatients/
45.  Hospitalization/
46.    (inpatient* or in-patient* or hospitalized or hospitalised 
or hospitalization*).ti,ab.
47.  or/44–46
48.  43 and 47
Concept: exercise
49.  exp exercise/or exp walking/
50.  exp Exercise Therapy/
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51.  Physical Fitness/
52.  Exercise Movement Techniques/
53.    (exercise* or physical exercise* or exercise therap* 
or walk* or ambulat* or physical fitness or physical 
a  ctivity).ti,ab.
54.  (exercise* adj5 train*).mp.
55.  (strength* adj5 train*).mp.
56.  exp ″Physical Therapy (Specialty)″/
57.  (physiother* or physical therap*).mp.
58.  Rehabilitation/
59.  rehabilitat*.mp.
60.  or/49–59
61.  48 and 60
62.  animals/not humans/
63.  61 not 62
64.  limit 63 to English
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